BioMarin Q1 revenue rises, beats estimates

BioMarin Pharmaceutical

04/05/2026 21:18

Overview

US rare disease drugmaker's Q1 revenue rose 3% yr/yr, beating analyst expectations

Adjusted EPS for Q1 beat consensus

Company raised 2026 revenue guidance after Amicus acquisition added new products

Outlook

BioMarin raises 2026 total revenue guidance to $3.825 bln-$3.925 bln, up from $3.325 bln-$3.425 bln

Company lowers 2026 Non-GAAP diluted EPS guidance to $4.85-$5.05 from $4.95-$5.15

More than 55% of 2026 revenue and two-thirds of Non-GAAP EPS expected in 2H26

Result Drivers

ENZYME THERAPIES GROWTH - Revenue growth in Q1 was driven by increased sales of VIMIZIM, NAGLAZYME, and BRINEURA, and new patient demand for PALYNZIQ following label expansion

PORTFOLIO EXPANSION - Addition of GALAFOLD and POMBILITI + OPFOLDA from Amicus acquisition strengthened and accelerated growth outlook

HIGHER OPERATING COSTS - Increased SG&A and R&D expenses, a $31 mln NAGLAZYME manufacturing charge, and costs tied to Amicus deal weighed on profitability

Company press release: ID:nPn8GWjsBa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$766 mln
$756 mln (21 Analysts)
Q1 Adjusted EPS
Beat
$0.76
$0.75 (16 Analysts)
Q1 EPS
$0.54
Q1 Net Income
$106 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)